Biotech Firm Tiziana Life Sciences to Showcase Drug Candidate at Saudi Innovation Forum

Tiziana Life Sciences has been invited to present at the Life Science Innovation Forum in Riyadh, Saudi Arabia. The conference aims to connect drug developers and research groups with investors and policymakers, supporting the country's National Biotechnology Strategy. The company will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody being developed as a nasal spray for neuroinflammation conditions.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a clinical-stage biopharmaceutical company, has been invited to present at the 2025 Life Science Innovation Forum (LSIF) in Riyadh, Saudi Arabia. The event, scheduled for October 1-2, aims to connect drug developers and research groups with investors and policymakers, aligning with Saudi Arabia's National Biotechnology Strategy Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia^[1].

Tiziana Life Sciences will showcase its lead drug candidate, foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is being developed as a nasal spray for neuroinflammation conditions, specifically Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). The drug has shown promising results in clinical trials, with 14 patients in an open-label Expanded Access Program (EA) Program (NCT06802328) experiencing either an improvement or stability of disease within 6 months Tiziana Life Sciences to Advance Anti-Inflammation Therapy Candidate^[2].

The LSIF 2025 will feature presentations from leading biotech companies, panel discussions, and networking sessions, facilitating investment, collaboration, and strategic partnerships. Tiziana Life Sciences' participation represents an opportunity to engage with global investors and explore potential collaborations to advance its mission of delivering next-generation immunotherapy solutions Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia^[1].